Obbligazione AstraZen PLC 0.7% ( US046353AV09 ) in USD

AstraZen PLC

100 USD ▲

Regno Unito

US046353AV09 ( in USD )

0.7% per anno ( pagato 2 volte l'anno)

07/04/2026

Prospetto opuscolo dell'obbligazione AstraZeneca PLC US046353AV09 en USD 0.7%, scadenza 07/04/2026

2 000 USD

1 200 000 000 USD

046353AV0

BBB+ ( Lower medium grade - Investment-grade )

A3 ( Upper medium grade - Investment-grade )

08/04/2026 ( In 59 giorni )

AstraZeneca PLC è una società biofarmaceutica multinazionale anglo-svedese che si concentra sulla ricerca, lo sviluppo, la produzione e la commercializzazione di farmaci con prescrizione medica in diverse aree terapeutiche.

Un'opportunità di investimento nel settore farmaceutico emerge con l'obbligazione emessa da AstraZeneca PLC, gigante biofarmaceutico globale con sede nel Regno Unito, rinomato per la sua leadership nella ricerca, sviluppo e commercializzazione di farmaci innovativi per il trattamento di malattie in aree terapeutiche chiave come l'oncologia, le malattie cardiovascolari, renali e metaboliche, e le malattie respiratorie e immunologiche. L'emissione, identificata dal codice ISIN US046353AV09 e dal CUSIP 046353AV0, è denominata in Dollari Statunitensi (USD) e presenta un prezzo attuale di mercato pari al 100% del valore nominale. Questo strumento finanziario offre un tasso d'interesse annuale dello 0,7%, con pagamenti semestrali, e giungerà a scadenza il 7 aprile 2026. La dimensione totale dell'emissione ammonta a 1.200.000.000 USD, rendendola una significativa operazione di raccolta fondi sul mercato internazionale, con un taglio minimo di acquisto fissato a 2.000 USD, rendendola accessibile a un'ampia platea di investitori. La solidità finanziaria dell'emittente è rafforzata dalle valutazioni di credito attribuite dalle principali agenzie di rating: un solido rating "BBB+" da Standard & Poor's (S&P) e un "A3" da Moody's, attestando un buon livello di affidabilità creditizia per l'azienda. Questa obbligazione rappresenta quindi un'opzione per gli investitori che cercano esposizione al settore farmaceutico attraverso un emittente consolidato e con un profilo di rischio moderato.

CALCULATION OF REGISTRATION FEE

Maximum Aggregate
Amount of
Title of Each Class of Securities Offered

Offering Price
Registration Fee(1)
0.700% Notes due 2026

$1,200,000,000
$155,760
1.375% Notes due 2030

$1,300,000,000
$168,740
2.125% Notes due 2050

$500,000,000
$64,900
Total

$3,000,000,000
$389,400
(1) Calculated in accordance with Rule 457(r) under the Securities Act of 1933, as amended.
PROSPECTUS SUPPLEMENT
Filed pursuant to Rule 424(b)(2)
(To Prospectus dated November 8, 2019)
Registration No. 333-234586

AstraZeneca PLC
$3,000,000,000

$1,200,000,000 0.700% Notes due 2026
$1,300,000,000 1.375% Notes due 2030
$500,000,000 2.125% Notes due 2050

The notes offered by this prospectus supplement comprise $1,200,000,000 0.700% Notes due 2026 (the "2026
Notes"), $1,300,000,000 1.375% Notes due 2030 (the "2030 Notes") and $500,000,000 2.125% Notes due 2050 (the
"2050 Notes", and together with the 2026 Notes and the 2030 Notes, the "Notes"). The 2026 Notes wil bear interest at a
rate of 0.700% per year. The 2030 Notes wil bear interest at a rate of 1.375% per year. The 2050 Notes wil bear interest
at a rate of 2.125% per year. Interest on the 2026 Notes wil be payable semi-annual y in arrears on April 8 and October 8
of each year, beginning on April 8, 2021. Interest on the 2030 Notes and the 2050 Notes wil be payable semi-annual y in
arrears on February 6 and August 6 of each year, beginning on February 6, 2021.
The Notes of any series are redeemable in whole but not in part prior to their respective maturity dates upon the
occurrence of certain tax events described herein. In addition, we may redeem the Notes of any series, in whole or in
part, from time to time at the applicable redemption prices described herein.
The Notes wil constitute unsecured and unsubordinated indebtedness of AstraZeneca PLC and wil rank equal y with
al other unsecured and unsubordinated indebtedness of AstraZeneca PLC from time to time outstanding.
The Notes are being offered global y for sale in jurisdictions where it is lawful to make such offers and sales. We
intend to apply to list the Notes on the New York Stock Exchange.

Investing in the Notes involves risks.

See "Risk Factors" beginning on page S-10 of this prospectus supplement and on page 5 of the attached
prospectus.

Neither the U.S. Securities and Exchange Commission (the "SEC") nor any other regulatory body has
approved or disapproved of the Notes or determined if this prospectus supplement or the accompanying
prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

Proceeds to
AstraZeneca
PLC
Underwriting
(before
Price to Public(1)
Discounts
expenses)
Per 2026 Note
99.595%
0.225%
99.370%
Total for 2026 Notes
$1,195,140,000
$2,700,000
$1,192,440,000
Per 2030 Note
99.712%
0.325%
99.387%
Total for 2030 Notes
$1,296,256,000
$4,225,000
$1,292,031,000
Per 2050 Note
97.906%
0.650%
97.256%
Total for 2050 Notes
$489,530,000
$3,250,000
$486,280,000
Total
$2,980,926,000
$10,175,000
$2,970,751,000

1 Plus interest accrued on the Notes from August 6, 2020, if any.

We expect to deliver the Notes to investors in registered book-entry form only through the facilities of The Depository
Trust Company ("DTC") on or about August 6, 2020. Beneficial interests in the Notes wil be shown on, and transfers
thereof wil be effected only through, records maintained by DTC and its direct and indirect participants, including
Clearstream Banking, S.A. ("Clearstream, Luxembourg"), and Euroclear Bank SA/NV ("Euroclear").

Joint Book-Running Managers

BofA Securities
HSBC
Mizuho Securities

Co-Managers

Barclays
Citigroup
Deutsche Bank
Goldman Sachs
J.P. Morgan
Morgan Stanley
Securities
& Co. LLC

Prospectus Supplement dated August 3, 2020.

Table of Contents

Prospectus Supplement

Page
About This Document
2
Where You Can Find More Information
2
Incorporation of Documents by Reference
2
Forward-Looking Statements
3
Summary
5
The Offering
6
Risk Factors
10
Use of Proceeds
11
Indebtedness and Capitalization
12
Description of Notes
13
Taxation
18
Clearance and Settlement
19
Underwriting
20
Sel ing Restrictions
21
Validity of the Notes
21
Experts
21

Prospectus
About This Prospectus
5
AstraZeneca PLC
5
Risk Factors
5
Forward-Looking Statements
7
Enforceability of Certain Civil Liabilities
9
Where You Can Find More Information About Us
9
Incorporation of Documents by Reference
9
Use of Proceeds
10
Legal Ownership
11
Description of Debt Securities
12
Clearance and Settlement
26
Certain UK and US Federal Tax Considerations
30
United Kingdom Taxation
30
United States Taxation
33
Plan of Distribution
38
Legal Matters
40
Experts
40
Changes in Registrant's Certifying Accountant
41

We have not, and the underwriters have not, authorized any other person to provide you with any information other
than the information contained in this prospectus supplement, the accompanying prospectus and the documents
incorporated by reference herein and therein. Neither we nor the underwriters take responsibility for, or provide any
assurance as to the reliability of, any different or additional information. Neither we nor the underwriters are making an
offer to sel the Notes in any jurisdiction where the offer or sale is not permitted. You should assume the information
appearing in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference
herein and therein are accurate only as of their respective dates. Our business, financial condition, results of operations
and prospects may have changed since those dates.

S-1

Table of Contents
ABOUT THIS DOCUMENT

This document is in two parts. The first part is the prospectus supplement, which describes the specific terms of the
Notes we are offering and certain other matters relating to us and our results of operations and financial condition. The
second part, the attached prospectus, gives more general information about securities we may offer from time to time,
some of which does not apply to the Notes we are offering. General y, when we refer to the prospectus, we are referring
to both parts of this document combined. If the description of the Notes in the prospectus supplement differs from the
description in the attached prospectus, the description in the prospectus supplement supersedes the description in the
attached prospectus.

WHERE YOU CAN FIND MORE INFORMATION

We file annual reports with the SEC on Form 20-F, and furnish other information on Form 6-K to the SEC. Our SEC
filings are available to the public over the internet at the SEC's website at http://www.sec.gov. These documents are also
available on our website at http://www.astrazeneca.com. The contents of our website are not incorporated into, and do
not form a part of, this prospectus supplement.

INCORPORATION OF DOCUMENTS BY REFERENCE

The SEC al ows us to "incorporate by reference" the information we file with or furnish to them, which means that we
can disclose important information to you by referring you to those documents. The information incorporated by
reference is considered to be part of this prospectus supplement and the accompanying prospectus and later information
that we file with the SEC wil automatical y update or supersede this information. We incorporate by reference the
documents listed below and any of our future filings made with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), until such time as al of the securities covered by
this prospectus supplement have been sold:
· Our Annual Report on Form 20-F for the year ended December 31, 2019, filed with the SEC on March 3, 2020.
· Our Report on Form 6-K titled "Update on Phase I I DANUBE trial for Imfinzi and tremelimumab in unresectable,
Stage IV bladder cancer" filed with the SEC on March 6, 2020.
· Our Report on Form 6-K titled "Imfinzi confirmed a sustained overal survival benefit in final analysis of the Phase
I I CASPIAN trial in 1st-line extensive-stage smal cel lung cancer" filed with the SEC on March 17, 2020.
· Our Report on Form 6-K titled "Farxiga Phase I I DAPA-CKD trial wil be stopped early after overwhelming efficacy in
patients with chronic kidney disease" filed with the SEC on March 30, 2020.
· Our Report on Form 6-K titled "Bevespi Aerosphere approved in China for patients with COPD" filed with the SEC
on May 18, 2020.
· Our Report on Form 6-K titled "Enhertu granted Orphan Drug Designation in the US for gastric cancer" filed with
the SEC on May 22, 2020.
· Our Report on Form 6-K titled "Tagrisso demonstrated unprecedented disease-free survival in the adjuvant
treatment of Stage IB-I IA patients with EGFR-mutated lung cancer" filed with the SEC on May 29, 2020.
· Our Report on Form 6-K titled "Brilinta approved in the US to reduce the risk of a first heart attack or stroke in
high-risk patients with coronary artery disease" filed with the SEC on June 1, 2020.
· Our Report on Form 6-K titled "Lynparza recommended for approval in EU by CHMP for BRCA-mutated metastatic
pancreatic cancer" filed with the SEC on June 1, 2020.
· Our Report on Form 6-K titled "Breztri Aerosphere approved in the US for the maintenance treatment of COPD"
filed with the SEC on July 24, 2020.

S-2

Table of Contents
· Our Report on Form 6-K titled "AstraZeneca and Dai chi Sankyo enter col aboration to develop and commercialise
new antibody drug conjugate" filed with the SEC on July 27, 2020.
· Our Report on Form 6-K titled "Calquence recommended for approval in the EU by CHMP for chronic lymphocytic
leukaemia" filed with the SEC on July 27, 2020.
· Our Report on Form 6-K titled "Imfinzi recommended for approval in the EU by CHMP for extensive-stage smal cel
lung cancer" filed with the SEC on July 27, 2020.
· Our Report on Form 6-K titled "Farxiga met al primary and secondary endpoints in groundbreaking Phase I I DAPA-
CKD trial for the treatment of patients with chronic kidney disease" filed with the SEC on July 28, 2020.
· Our Report on Form 6-K titled "New Remuneration Committee Chairman" filed with the SEC on July 29, 2020.
· Our Report on Form 6-K titled "Tagrisso granted Breakthrough Therapy Designation in the US for the adjuvant
treatment of patients with Stage IB-I IA EGFR-mutated lung cancer" filed with the SEC on July 30, 2020.
· Our Report on Form 6-K titled "H1 2020 results" filed with the SEC on July 31, 2020 but excluding the Independent
Review Report to AstraZeneca PLC on pages 40 and 41.
· All other documents we file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this
prospectus supplement and prior to the termination of the offering of the Notes and, to the extent designated
therein, reports furnished to the SEC on Form 6-K, in each case with effect from the date that such document or
report is so filed or furnished.
We wil provide without charge to each person, including any beneficial owner, to whom this prospectus is delivered,
upon his or her written or oral request, a copy of any or al documents referred to above which have been or may be
incorporated by reference into this prospectus other than exhibits which are not specifical y incorporated by reference
into those documents. You can request those documents from either of the below:

AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
England, United Kingdom
The Company Secretary
Tel. No.: +44-20-3749-5000
Investor Relations
Tel. No.: +44-20-3749-5824

FORWARD-LOOKING STATEMENTS

From time to time, we may make statements regarding our assumptions, projections, expectations, intentions or
beliefs about future events. These statements constitute "forward-looking statements" for purposes of the US Private
Securities Litigation Reform Act of 1995. We caution that these statements may and often do vary from actual results and
the differences between these statements and actual results can be material. Accordingly, we cannot assure you that
actual results wil not differ material y from those expressed or implied by the forward-looking statements. You should
read the section entitled "Cautionary statement regarding forward-looking statements" incorporated by reference into
our annual report on Form 20-F for the year ended December 31, 2019, and included in our Report on Form 6-K titled "H1
2020 results" dated July 31, 2020 and the section entitled "Forward-Looking Statements" on pages 7, 8 and 9 of the
attached prospectus for additional information.

S-3

Table of Contents
We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events
discussed in this prospectus supplement, the attached prospectus or the information incorporated by reference, might
not occur.

S-4

Table of Contents
SUMMARY

Unless otherwise stated in this prospectus supplement or unless the context otherwise requires, the words
"Company", "we", "our" and "us" refer to AstraZeneca PLC.
The fol owing summary contains basic information about this offering. It may not contain al the information that is
important to you. The Description of Notes section of this prospectus supplement and the Description of Debt Securities
section of the attached prospectus contain more detailed information regarding the terms and conditions of the Notes.
The fol owing summary is qualified in its entirety by reference to the detailed information appearing elsewhere or
incorporated by reference in this prospectus supplement and in the attached prospectus. Capitalized terms not defined in
this section have the meanings specified in our Annual Report on Form 20-F for the year ended December 31, 2019, filed
with the SEC on March 3, 2020 incorporated by reference herein.

Overview
We are a global, science-led, patient-focused pharmaceutical company that focuses on the discovery, development,
manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases in three main
Therapy Areas: Oncology, Cardiovascular, Renal & Metabolism and Respiratory & Immunology.
Backed by a track record of pharmaceutical innovation over more than 70 years, we have a broad range of
marketed medicines that continue to make a positive difference in healthcare. In addition to our pipeline of products in
the discovery and development phases, our pipeline includes life-cycle management initiatives for approved products
to bring further benefit for patients and maximize their commercial potential. As at December 31, 2019, our range of
medicines included nine products with annual sales of over $1 bil ion each.
We are active in over 100 countries worldwide, with three strategic research and development centers in Sweden,
the United Kingdom and the United States, and operations sites in 16 countries. As at December 31, 2019, we
employed approximately 70,600 people with approximately 48.3% in Emerging Markets, 26.5% in Europe, 18.1% in the
United States and 7.1% in the Established Rest of World (including Japan, Canada, Australia and New Zealand). Our
principal executive office is located at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA and
our telephone number is +44-20-3749-5000.
We refreshed our strategic priorities in 2019, enhancing our focus on growth through innovation fostering a
patient-centric culture and embedding it across the organization, doing more with technology, digital and data, and
advancing cutting-edge science. Our strategic priorities are:
1. Deliver Growth and Therapy Area Leadership by focusing on delivering the potential of already-developed
medicines and aiming to ensure that AstraZeneca is in a leadership position in each of its main Therapy Areas
by 2025.
2. Accelerate innovative science by focusing on how AstraZeneca can bring through the next wave of innovation
from its industry-leading pipeline.
3. Be a great place to work by carrying forward the priority from the 2013 strategy and focusing on patients,
leading in sustainability and performing as an enterprise team.
Our ADSs are listed on the New York Stock Exchange under the symbol "AZN". Our ordinary shares are admitted to
trading on the London Stock Exchange under the symbol "AZN" and are also listed on the Stockholm Stock Exchange
under the symbol "AZN".

S-5

Table of Contents
THE OFFERING

Issuer
AstraZeneca PLC.
Notes Being Offered
$1,200,000,000 aggregate principal amount of 0.700%
Notes due 2026 (the "2026 Notes").
$1,300,000,000 aggregate principal amount of 1.375%
Notes due 2030 (the "2030 Notes").
$500,000,000 aggregate principal amount of 2.125%
Notes due 2050 (the "2050 Notes").
The 2026 Notes, the 2030 Notes and the 2050 Notes are
together referred to herein as the "Notes".
The Notes wil be issued under an indenture dated as of
April 1, 2004 (the "Indenture") between us and The Bank
of New York Mel on, and the terms of the securities wil
be set forth in an Officers' Certificate to be dated August
6, 2020. The 2026 Notes, the 2030 Notes and the 2050
Notes wil each be treated as a separate series of Notes
and, as such, wil vote and act, and may be redeemed,
separately.
PROVISIONS APPLICABLE TO THE NOTES
Maturity Dates
2026 Notes: April 8, 2026.
2030 Notes: August 6, 2030.
2050 Notes: August 6, 2050.
Interest Rate
The 2026 Notes wil bear interest from August 6, 2020 at

a rate of 0.700% per annum, payable semi-annual y.
The 2030 Notes wil bear interest from August 6, 2020 at
a rate of 1.375% per annum, payable semi-annual y.
The 2050 Notes wil bear interest from August 6, 2020 at
a rate of 2.125% per annum, payable semi-annual y.
Interest Payment Dates
Interest on the 2026 Notes wil be paid semi-annual y in
arrears on April 8 and October 8 of each year,
commencing April 8, 2021 (each, a "2026 Interest
Payment Date").
Interest on the 2030 Notes and the 2050 Notes wil be
paid semi-annual y in arrears on February 6 and August 6
of each year, commencing February 6, 2021 (together
with each 2026 Interest Payment Date, each an "Interest
Payment Date").
Interest Periods
The first interest period for the Notes wil be the period
from and including the issue date to but excluding the
first Interest Payment Date. Thereafter,

S-6

Table of Contents

the interest periods for the Notes wil be the periods from
and including the Interest Payment Dates to but excluding
the immediately succeeding Interest Payment Date
(together with the first interest period, each an "Interest
Period"). The final Interest Period wil be the period from
and including the Interest Payment Date immediately
preceding the maturity date to the maturity or the
redemption date.
Day Count Convention
360-day year and twelve 30-day months.
Optional Redemption
We may redeem the Notes of any series, in whole or in
part, from time to time as fol ows: (i) prior to the
applicable Par Cal Date (as set forth below), at a
redemption price equal to the greater of (A) 100% of the
principal amount of the Notes to be redeemed, and (B) as
determined by the Quotation Agent, the sum of the
present values of the remaining scheduled payments of
principal and interest on the Notes to be redeemed
(assuming for this purpose that such series of Notes
matured on the applicable Par Cal Date and not including
any portion of such payments of interest accrued as of the
date of redemption) discounted to the date of redemption
on a semiannual basis (assuming a 360-day year
consisting of twelve 30-day months) at the Treasury Rate
plus the applicable Make-Whole Spread (as set forth
below) and (i ) on or after the applicable Par Cal Date, at a
redemption price equal to 100% of the principal amount of
the Notes to be redeemed, plus, in each case, accrued
interest thereon to but excluding the date of redemption.
See "Description of Notes -- Redemption -- Optional
Redemption".
Par Cal Date
2026 Notes: March 8, 2026.
2030 Notes: May 6, 2030.
2050 Notes: February 6, 2050.
Make-Whole Spread
2026 Notes: 10 basis points.
2030 Notes: 15 basis points.
2050 Notes: 15 basis points.
Optional Tax Redemption
In the event of various tax law changes and other limited
circumstances that require us to pay additional amounts
as described under "Description of Notes -- Redemption --
Optional Tax Redemption", we may redeem in whole, but
not in part, any series of the Notes prior to maturity at a
redemption price equal to 100% of their principal amount
plus accrued interest thereon to but excluding the date of
redemption.

S-7